FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2017

POSSESSION USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
MEDICAL ONCOLOGY
PAPER I
MEDONCO/J/17/17/I
Time 3 hours
Max. Marks 100
Important instructions:
• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.
• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Method of clonality testing in Non-Hodgkin's lymphoma.
List one important molecular abnormality in mantle cell,
follicular, chronic lymphocytic leukemia and anaplastic large
cell lymphoma.
Role of these abnormalities in pathogenesis of corresponding
lymphoma.

2. List drugs used for acute graft versus host disease (AGVHD)
following allogenic bone marrow/stem cell transplantation.
Compare cyclosporin and tacrolimus as regards to mechanism,
dose toxicity.
Treatment of steroid refractory AGVHD.

3. Radiation treatment and principles as applied to cervix cancer
stage II B.
List acute and late toxicities.
Mention 5 year survival rates for various stages of cancer
cervix.

4. Superior vena cava syndrome in children:
Causes.
Pathophysiology.
Diagnosis.
Treatment.

5. Trastuzumab Vs Lapatinib:
Mechanism of action of Trastuzumab.
Mechanism of action of Lapatinib.
Indications.
Differences between the two.
Results with their treatment.

P.T.O.
FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2017

POSSESSION USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
MEDICAL ONCOLOGY
PAPER I
6. Techniques for testing genetic predisposition for colon cancer.
Clinical implications for MSI testing in colon cancer.
5+5
7. List targeted oral agents for chronic lymphocyte leukemia
(CLL).
List various prognostic factors for this condition.
Outline treatment for an 80 year old male with Rai stage III
CLL.

8. A 50 year old male has been diagnosed to have right
supraclavicular lymph node and right hilar mass.
Brielfy describe the approach for diagnostic evaluation.
List oral targeted therapy for lung cancer with their rationale.
Briefly mention mechanism of resistance to oral tyrosine kinase
inhibitors used for lung cancer.

9. PD-1 and PDL-1 inhibitors and their mechanism.
Similarities and differences between CAR-T cells and
Blinatumomab for the treatment of acute lymphoblastic
leukemia.
4+6
10. Response assessment criteria in cancer treatment:
Mention different types of response assessment.
WHO response assessment criteria.
How will you assess response in a patient of lung cancer
treated with PDL-1 inhibitor?